This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GGCX · Western blot design guide
GGCX Western Blot Planning Guide
Plan a GGCX Western blot around the catalog-observed 87.6 kDa band, image-backed A02643-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
GGCX Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 87.6 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Liver | |
| Negative control | Soft tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 87.6 kDa |
| ⓘ | Localization | Endoplasmic reticulum membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse |
Section 1
Real Curated GGCX Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Liver |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02643-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected GGCX Western Blot Band Size?
Use the product-observed 87.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 87.6 kDa | Matches the authoritative product WB observation. |
| 87.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected GGCX appearancePlan around 87.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 87.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 87.6 kDa from UniProt P38435; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02643-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 87.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing GGCX band
A02643-1 · GGCX
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for GGCX Western blot
🧪Use Liver as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Liver (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for GGCX
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Liver | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced GGCX Western Blot Tips
Deeper troubleshooting and optimisation questions for GGCX, answered from its protein features.
Which band should guide the blot?
Use 87.6 kDa, the observation attached to the authoritative A02643-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 87.6 kDa expectation.
Which positive control should I start with?
Start with Liver, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for GGCX Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02643-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
GGCX Western Blot Reagents
Human/Mouse-reactive GGCX Western blot reagents with authoritative product imagery.
Real WB data
Anti-GGCX Antibody Picoband®
Cat # A02643-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P38435
- Human Protein Atlas — GGCX
- A02643-1 product record
- PMC13477297 — Systematic Identification of Therapeutic Targets and Repurposed Drugs for Stroke: From Genome Causal Analysis to Multilevel Validation (Journal of the American Heart Association, 2026)
- PMC13455504 — Molecular insights into the comorbidity of vitamin K-dependent clotting factor deficiency and chondrodysplasia punctata (Journal of thrombosis and haemostasis : JTH, 2025)
